GlaxoSmithKline's Relenza gets FDA approval for flu prevention

By Elaine Rigoli

Tampa, Fla., March 29 - The Food and Drug Administration approved the use of Relenza (zanamivir for inhalation) for prevention of influenza in adults and children five years of age and older.

Relenza, an antiviral medication, was previously approved for the treatment of influenza A and B virus infections in adults and children.

Tamiflu (oseltamivir phosphate) previously was approved for both prevention and treatment of flu, according to a news release.

Yesterday's approval of Relenza for prevention provides Americans with another option for the prevention of influenza A and B infections, the release said.

Relenza has not been proven effective for treatment of influenza in people with underlying airways disease, or for prevention of influenza in nursing homes.

The drug is also not a substitute for the flu vaccine, which is the primary means for preventing influenza.

GlaxoSmithKline manufactures and distributes Relenza in Research Triangle Park, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.